Earnings Scheduled For February 23, 2022
Companies Reporting Before The Bell
• Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter.
Earnings Scheduled For November 3, 2021
Companies Reporting Before The Bell
• R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.
‘Best Penny Stocks To Buy For A Short Squeeze? 10 To Watch Today’ -Pennystocks.com; Article Mentions Voyager Therapeutics, Kala Pharma, Electrameccanica, Meta Materials, Clovis Oncology
https://pennystocks.com/featured/2021/11/01/best-penny-stocks-to-buy-short-squeeze-10-to-watch-today/
Clovis Oncology Says Pan-Cancer Analysis Suggests Fibroblast Activation Protein (FAP) Is Attractive Target For Peptide-Targeted Radionuclide Therapy With FAP-2286
Clovis Oncology, Inc. (NASDAQ:CLVS) announced that nonclinical data describing the expression of fibroblast activating protein (FAP) in a variety of solid tumor types will be presented during the AACR-NCI-EORTC Virtual
Benzinga Pro’s Top 5 Stocks To Watch For Friday, Sept. 24, 2021: TWTR, CRM, ZIVO, CLVS, MRM
Today's 5 Stock Ideas:
Twitter (TWTR) - Shares spiked over the $65.50 level Thursday afternoon following news the company will add tipping via bitcoin to its platform. Twitter also said it will be
HC Wainwright & Co. Maintains Buy on Clovis Oncology, Lowers Price Target to $9
HC Wainwright & Co. analyst Edward White maintains Clovis Oncology (NASDAQ:CLVS) with a Buy and lowers the price target from $10 to $9.
Clovis Oncology Retires Remaining 2021 Notes And Raises Additional Capital Through Its ATM Equity Offering Program
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has paid off in full at maturity the remaining $64.4 million in principal amount outstanding of its 2.50% convertible senior notes due 2021. In addition, the
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen’s Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 19)
HC Wainwright & Co. Maintains Buy on Clovis Oncology, Lowers Price Target to $10
HC Wainwright & Co. analyst Edward White maintains Clovis Oncology (NASDAQ:CLVS) with a Buy and lowers the price target from $12 to $10.
Clovis Oncology Earlier Reported Q2 Adj. EPS $(0.59) Misses $(0.56) Estimate, Sales $36.82M Miss $41.12M Estimate
Clovis Oncology (NASDAQ:CLVS) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.56) by 5.36 percent. This is a 46.85 percent increase over losses of $(1.11) per share from